MyFinsight
Home
Blog
About
Proceeds from maturities
of marketable...
$225M
(-63.41%↓ Y/Y)
Proceeds from issuance of
common stock pursuant...
$16M
(433.33%↑ Y/Y)
Proceeds from sales of
marketable securities
$9M
(-86.96%↓ Y/Y)
Net cash provided by
investing activities
$52M
(-69.23%↓ Y/Y)
Net cash provided by
financing activities
$16M
(-91.75%↓ Y/Y)
Canceled cashflow
$182M
Net increase
(decrease) in cash, cash...
-$51M
(-152.04%↓ Y/Y)
Canceled cashflow
$68M
Stock-based compensation
expense
$15M
(-51.61%↓ Y/Y)
Depreciation and
amortization
$3M
(-40.00%↓ Y/Y)
Noncash lease expense
$2M
(-33.33%↓ Y/Y)
Other items, net
$1M
Purchases of marketable
securities
$182M
(-64.59%↓ Y/Y)
Net cash used in
operating activities
-$119M
(55.09%↑ Y/Y)
Canceled cashflow
$21M
Net loss
-$91M
(18.75%↑ Y/Y)
Deferred revenue ((48)
and (188) to a...
-$37M
(80.32%↑ Y/Y)
Accounts payable ((12)
and 13 to a related...
-$5M
(-145.45%↓ Y/Y)
Receivable from
collaboration partners ( and 2...
$3M
(160.00%↑ Y/Y)
Other liabilities
-$2M
(83.33%↑ Y/Y)
Amortization of discounts on
marketable securities
$2M
(-71.43%↓ Y/Y)
Back
Back
Cash Flow
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)
source: myfinsight.com